log  
logo
a Journal of Postdoctoral Research and Postdoctoral Affairs.
logo
    ISSN : 2328-9791
left right
 
 
Task Force for Cystic Fibrosis Extension
     
 
Author(s) : Bandiera T, Pedemonte N, and Galietta L.J.V.
Address : Istituto Italiano di Tecnologia (IIT), Genova, Istituto Giannina Gaslini(IGG), Genova, and Telethon Institute for Genetics and Medicine (TIGEM), Pozzuoli, Italy.
flaminia.malvezzi@fibrosicisticaricerca.it

Background The most frequent mutation among patients with cystic fibrosis (CF), F508del, causes defective maturation and early degradation of CFTR protein1. The F508del defect can be targeted with compounds known as correctors2.  Proteins carrying F508del and other mutations also show a channel gating defect that can be addressed with another type of compounds called potentiators3.  Currently, there are no F508del-CFTR correctors with adequate efficacy in human. Therefore, new compounds are needed4.

Hypothesis and objectives The project aims at the selection of a compound to progress to preclinical development, and at starting preclinical development activities. In parallel, activities to identify a backup compound will be conducted.

 
btm
 
top
 
 
 
 
 
btm

 
footer
 
 
home phone mail info@postdocjournal.com
 
twitter facebook social icon Social link You Tube sky
Click Here